Private prescribing has expanded faster than oversight
Since the UK legalized prescribing of cannabis-based medicinal products in 2018, the private market has grown far faster than NHS use. Official data and freedom-of-information releases show private unlicensed cannabis items rising from 282,920 in 2023 to 659,293 in 2024, with volumes increasing sharply again through 2025 and 2026. Most products supplied privately are unlicensed medicines, meaning they have not received full regulatory approval for a specific indication.
That does not automatically make them unsafe, but it places greater responsibility on the prescriber to assess benefit and risk, monitor adverse effects and explain the limits of evidence to patients. NHS and NICE guidance states that initiation of unlicensed cannabis-based medicinal products should be by an appropriate specialist doctor, supported by clear monitoring and communication arrangements.
Oliver Robinson’s case became a warning sign
A Prevention of Future Deaths report issued by Coroner Catherine McKenna in February 2026 said Oliver Robinson had a history of depression, addictive tendencies and cannabis dependence. He received medicinal cannabis from Curaleaf Clinic for treatment-resistant depression from May 2022 until November 2023.

















